Please use this identifier to cite or link to this item:
|Title:||Astaxantin and Isoflavones Inhibit Benign Prostatic Hyperplasia in Rats by Reducing Oxidative Stress and Normalizing Ca/Mg Balance|
|Authors:||Semenov, A. L.|
Gubareva, E. A.
Ermakova, E. D.
Dorofeeva, A. A.
Tumanyan, I. A.
Radetskaya, E. A.
Yurova, M. N.
Aboushanab, S. A.
Kanwugu, O. N.
Fedoros, E. I.
Panchenko, A. V.
|Citation:||Astaxantin and Isoflavones Inhibit Benign Prostatic Hyperplasia in Rats by Reducing Oxidative Stress and Normalizing Ca/Mg Balance / A. L. Semenov, E. A. Gubareva, E. D. Ermakova et al. // Plants. — 2021. — Vol. 10. — Iss. 12. — 2735.|
|Abstract:||Benign prostatic hyperplasia (BPH) is a common pathology among aging men. Despite the broad pharmacological interventions, the available remedies to treat BPH are yet not devoid of side effects. Herbal compounds are suggested to be an alternative option for the BPH treatment. In our study, we evaluated the effect of kudzu isoflavones and astaxanthin on the BPH animal model. The animals were randomly divided into five groups: control; testosterone-induced BPH group; and three BPH-induced groups, which received intragastrically for 28 days finasteride (5 mg/kg) as a positive control, isoflavones (200 mg/kg), and astaxanthin (25 mg/kg). BPH was induced by castration of animals and subsequent subcutaneous injections of prolonged testosterone (25 mg/kg). Prostate index and histology, biochemical parameters, and antioxidant activity were evaluated. A significant decrease in prostate weight, immunohistochemical markers, and normalization of prostate Ca/Mg ratio was found in all treatment groups. Astaxanthin treatment also resulted in decreased epithelial proliferation and normalized superoxide dismutase activity. In conclusion, both isoflavones and astaxanthin inhibited BPH development at a level comparable to finasteride in terms of prostate weight, prostatic epithelium proliferation, and prostate tissue cumulative histology score. These results suggest that isoflavones and especially astaxanthin could serve as a potential alternative therapy to treat BHP. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.|
BENIGN PROSTATIC HYPERPLASIA
|metadata.dc.description.sponsorship:||Funding: This research was funded by Russian Science Foundation, grant number 20-65-47025.|
|RSCF project card:||20-65-47025|
|Appears in Collections:||Научные публикации, проиндексированные в SCOPUS и WoS CC|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.